earnings
confidence high
sentiment negative
materiality 0.80
Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business
MARAVAI LIFESCIENCES HOLDINGS, INC.
2024-Q3 EPS reported
-$0.87
revenue$202,779,000
- Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.
- Adjusted EBITDA $12.7M vs $11.9M in Q3 2023.
- FY2024 revenue guidance lowered to $255-265M (from prior outlook).
- Agreed to acquire Officinae Bio's DNA/RNA business (AI-driven platform); close expected early 2025.
- Nucleic Acid Production revenue $49.9M (down 2.5% YoY); Biologics Safety Testing $15.3M (down 2.5%).